RXi Reports Positive Phase 2 Clinical Trial Results for Treatment of Common Warts

published 9:08 pm ET May 18th, 2018

On May 18, RXi Pharmaceuticals Corporation (RXII) reported positive results from its phase 2 clinical trial of the drug Samcyprone for the treatment of common warts. After weekly application for 10 weeks, participants had a 97.7% positive immunotherapy response rate. 70% of participants experienced a reduction of at least 50% wart size. There is currently no prescription drug approved by the FDA for the treatment of common warts.

Rocket Tickers caught the news and sent an alert at 11:58 am. The next trade took place at 11:59 am for $2.45. The stock closed at $2.58 for a gain of over 5% on the event day.

Visit the Knowledge Center for more information about clinical trials and how to trade them.

Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.

Subscribe here if you would like to start receiving these signals in real-time and start trading!